Order Article Reprints

Ráduly AP, Sárkány F, Kovács MB, Bernát B, Juhász B, Szilvássy Z, Porszász R, Horváth B, Szentandrássy N, Nánási P, et al. The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications. International Journal of Molecular Sciences. 2023; 24(1):446. https://doi.org/10.3390/ijms24010446

Ráduly, Arnold Péter, Fruzsina Sárkány, Máté Balázs Kovács, Brigitta Bernát, Béla Juhász, Zoltán Szilvássy, Róbert Porszász, Balázs Horváth, Norbert Szentandrássy, Péter Nánási, and et al. 2023. "The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications" International Journal of Molecular Sciences 24, no. 1: 446. https://doi.org/10.3390/ijms24010446

Ráduly, A. P., Sárkány, F., Kovács, M. B., Bernát, B., Juhász, B., Szilvássy, Z., Porszász, R., Horváth, B., Szentandrássy, N., Nánási, P., Csanádi, Z., Édes, I., Tóth, A., Papp, Z., Priksz, D., & Borbély, A. (2023). The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications. International Journal of Molecular Sciences, 24(1), 446. https://doi.org/10.3390/ijms24010446